Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. These findings highlight the gap between widespread patient use of CBD for fibromyalgia and the current clinical evidence supporting that use. Clinicians should counsel patients that rigorous trial data do not yet support CBD as an effective treatment for fibromyalgia pain.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomised controlled trial addresses a significant evidence gap by rigorously evaluating cannabidiol efficacy in fibromyalgia, a condition where treatment options remain limited and off-label cannabis use is increasingly prevalent despite minimal clinical data. The double-blind, placebo-controlled design provides robust evidence that can inform clinical decision-making and help establish whether CBD merits consideration as an adjunctive therapeutic option for fibromyalgia pain management. Given the opioid crisis and limited efficacy of conventional analgesics in fibromyalgia, validated evidence for or against CBD could meaningfully impact treatment algorithms and patient counseling in clinical practice.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomized controlled trial provides valuable evidence on CBD’s role in fibromyalgia management, though the single-center design and undisclosed sample size limit generalizability to broader patient populations. The study’s rigorous double-blind, placebo-controlled methodology is commendable, yet fibromyalgia’s heterogeneous presentation and high placebo response rates in pain conditions warrant careful interpretation of any observed treatment effects. Key confounders such as concurrent medications, sleep quality, psychological comorbidities, and individual CBD metabolism variations are critical contextual factors that could substantially influence outcomes but may not be fully captured in the trial design. Clinically, while this research contributes to the evidence base, practitioners should continue individualizing CBD recommendations for fibromyalgia patients through careful patient selection, baseline pain assessment, and monitored dose titration rather than relying on CBD as a monotherapy, while remaining alert for drug-drug interactions and the need for complementary multimodal pain management strategies.